← Back to headlines
Halozyme (HALO) Stock Rated Buy on Strong Royalty Growth
Halozyme Therapeutics (HALO) has received a 'Buy' rating, driven by expectations of strong royalty growth.
2 May, 17:51 — 2 May, 17:51
Sources
Showing 1 of 1 sources
Related Stories
Lionel Richie Hospitalized in ICU Following St. Louis Concert
1h ago
Novartis Pauses Autoimmune Cell Therapy Trials After Patient Deaths
2h ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
12h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
15h ago